Kelvin Lam, Ph.D.

Founder and President
Simplex Pharma Advisors, Inc.

Kelvin Lam is the Founder and President of Simplex Pharma Advisors, Inc. He offers consulting expertise to biotechnology, pharmaceutical and academic institutions focusing on preclinical discovery research including identifying productive partners, project management, budgeting, and strategic planning as well as core screening lab set up, compound management, assay development and stem cell differentiation and induced pluripotent stem (iPS) cell screening.

Kelvin specializes in providing guidance to small biotech organizations to translate their visions into effective change to ensure on-time deliverables to sustain long-term productivity. He is a trusted thinking partner to create new ideas and a reliable advisor to provide strategic plans and to extend structured thinking. He is able to identify productive partnerships and help tailor your needs through his extensive professional network.

Previously, Kelvin held positions as Vice President of Blue Sky BioServices, Worcester, MA and a Director at the Harvard Stem Cell Institute (HSCI) at Harvard University, Cambridge, MA. Prior to this Kelvin had key research leadership and supervisory positions at Pfizer, Inc. and Scriptgen Pharmaceuticals specializing in High Throughput Screening (HTS), High Content Screening (HCS), lead profiling, library design, collection and management. Kelvin worked to establish the Stem Cell Special Interest Group (Stem Cell SIG) at the Society for Laboratory Automation and Screening (SLAS), and he was Co-chair of the 2009 and 2011 SLAS/HSCI/ISSCR Screening Stem Cells Conferences. He was on the Board of Directors of the Society of Biomolecular Screening (SBS). He was on the Editorial Board of Journal of Biomolecular Screening (SAGE) and was also a Guest Editor for the 2012 JBS Special Issue on Stem Cells. He is currently one of the Editors-in-Chief of Drug Discovery Today: Technologies (Elsevier) since 2003.

Kelvin holds a B.A. in Chemistry from University of Hawaii, Honolulu, HI and a Ph.D. in Biochemistry from Boston University, Boston MA. Kelvin completed his postdoctoral training at Dana Farber Cancer Institute and Massachusetts General Hospital Cancer Center affiliated with Harvard Medical School, Boston MA, USA.